Dr. Reddy's Laboratories Limited Cash Flow Conversion Efficiency
Dr. Reddy's Laboratories Limited cash flow conversion efficiency. Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has a cash flow conversion efficiency ratio of 0.029x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€10.91 Billion ≈ $12.75 Billion USD) by net assets (€375.76 Billion ≈ $439.30 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Dr. Reddy's Laboratories Limited (RDDA) market capitalisation for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Dr. Reddy's Laboratories Limited (2017–2025)
Cash flow conversion efficiency of Dr. Reddy's Laboratories Limited from 2017 to 2025. This chart illustrates how Dr. Reddy's Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Dr. Reddy's Laboratories Limited stock quote for real-time trading data and today's change.
Dr. Reddy's Laboratories Limited Cash Flow Conversion Ratio Explained
Dr. Reddy's Laboratories Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Dr. Reddy's Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their cash flow conversion efficiency. Review Dr. Reddy's Laboratories Limited free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DEUTSCHE WOHNEN ADRS/1/2
F:DWNP
|
0.029x |
|
China Southern Airlines Co Ltd Class A
SHG:600029
|
0.316x |
|
MARKS SPENCER ADR LS-25
F:MA6A
|
N/A |
|
Sangfor Technologies Inc Class A
SHE:300454
|
0.029x |
|
L E Lundbergföretagen AB (publ)
ST:LUND-B
|
0.020x |
|
Globus Medical
NYSE:GMED
|
0.086x |
|
Rambus Inc
NASDAQ:RMBS
|
0.065x |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
0.055x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy's Laboratories Limited from 2017 to 2025. Also see RDDA total assets for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €337.17 Billion ≈ $394.18 Billion |
€46.43 Billion ≈ $54.28 Billion |
0.138x | -14.97% |
| 2024-03-31 | €280.55 Billion ≈ $327.99 Billion |
€45.43 Billion ≈ $53.12 Billion |
0.162x | -35.95% |
| 2023-03-31 | €232.86 Billion ≈ $272.24 Billion |
€58.88 Billion ≈ $68.83 Billion |
0.253x | +71.38% |
| 2022-03-31 | €190.53 Billion ≈ $222.75 Billion |
€28.11 Billion ≈ $32.86 Billion |
0.148x | -27.70% |
| 2021-03-31 | €174.98 Billion ≈ $204.57 Billion |
€35.70 Billion ≈ $41.74 Billion |
0.204x | +5.97% |
| 2020-03-31 | €154.99 Billion ≈ $181.20 Billion |
€29.84 Billion ≈ $34.89 Billion |
0.193x | -5.96% |
| 2019-03-31 | €140.20 Billion ≈ $163.91 Billion |
€28.70 Billion ≈ $33.56 Billion |
0.205x | +43.61% |
| 2018-03-31 | €126.46 Billion ≈ $147.85 Billion |
€18.03 Billion ≈ $21.08 Billion |
0.143x | -17.80% |
| 2017-03-31 | €124.04 Billion ≈ $145.02 Billion |
€21.51 Billion ≈ $25.15 Billion |
0.173x | -- |
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more